

Ryohei Ohtani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/993201/publications.pdf>

Version: 2024-02-01

24
papers

333
citations

840776

11
h-index

839539

18
g-index

25
all docs

25
docs citations

25
times ranked

595
citing authors

#	ARTICLE	IF	CITATIONS
1	Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 32-40.	1.9	15
2	Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 377-383.	1.9	18
3	Cryptococcal Meningitis in a Fingolimod-Treated Patient. <i>Neurology: Clinical Practice</i> , 2021, 11, e549-e550.	1.6	2
4	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110068.	1.0	6
5	Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders. <i>Journal of Neurology</i> , 2021, , 1.	3.6	1
6	Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2020, 26, 128-129.	3.0	4
7	Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 132-139.	1.9	20
8	Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder. <i>Clinical and Experimental Immunology</i> , 2020, 202, 239-248.	2.6	6
9	Comparison of brain atrophy in patients with multiple sclerosis treated with first-versus second-generation disease modifying therapy without clinical relapse. <i>European Journal of Neurology</i> , 2020, 27, 2056-2061.	3.3	4
10	Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis. <i>PLoS ONE</i> , 2020, 15, e0224419.	2.5	11
11	The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. <i>Journal of Neuroimmunology</i> , 2019, 336, 577021.	2.3	20
12	Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2019, 403, 78-84.	0.6	8
13	Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731875969.	1.0	14
14	Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines. <i>Clinical and Experimental Immunology</i> , 2018, 193, 47-54.	2.6	14
15	Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration. <i>Journal of Neurology</i> , 2018, 265, 1145-1150.	3.6	15
16	Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. <i>Journal of the Neurological Sciences</i> , 2018, 385, 64-68.	0.6	10
17	Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity. <i>Journal of Neuroimmunology</i> , 2017, 305, 131-134.	2.3	5
18	Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. <i>Clinica Chimica Acta</i> , 2017, 469, 144-149.	1.1	32

#	ARTICLE	IF	CITATIONS
19	Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2017, 305, 102-107.	2.3	35
20	Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1072-1084.	3.0	48
21	Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder. <i>PLoS ONE</i> , 2017, 12, e0184012.	2.5	10
22	Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 367, 375-379.	0.6	16
23	Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis. <i>Clinica Chimica Acta</i> , 2016, 453, 131-133.	1.1	10
24	Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1371-1375.	3.0	9